文献速递免疫规划慢病防控与筛查

带状疱疹患者疼痛报告:带状疱疹活疫苗的增量益处

Patient report of herpes zoster pain: Incremental benefits of zoster vaccine live.
PubMed 文献 · Vaccine · 2019-05-11

本研究在Kaiser Permanente Southern California开展前瞻性队列研究,随访509名接种和509名未接种带状疱疹活疫苗(ZVL)的≥60岁实验室确诊带状疱疹患者,于诊断后5天内及30、60、90天评估疼痛。结果显示ZVL与各时间点带状疱疹相关疼痛风险显著降低相关,接种者带状疱疹后神经痛(PHN)风险为9.2% vs 15.4%(aRR=0.594,95%CI:0.413,0.854)。

要点

  • 接种ZVL的带状疱疹患者PHN风险显著低于未接种者(9.2% vs 15.4%)。
  • 接种者报告疼痛≥7的风险也显著降低(2.0% vs 4.8%)。
  • 无论是否接种,<70岁成人PHN风险低于≥70岁者。

核心结论

  • ZVL除预防带状疱疹外,还能降低接种后仍发生带状疱疹者的相关疼痛并预防PHN。

研究设计与样本

  • 前瞻性队列研究,纳入2012年1月18日至2015年2月26日期间Kaiser Permanente Southern California的≥60岁实验室确诊带状疱疹成员,接种与未接种ZVL各509人。

主要发现

  • 接种与未接种者PHN风险分别为9.2%和15.4%(aRR=0.594,95%CI:0.413,0.854)。
  • 接种与未接种者报告疼痛≥7的比例分别为2.0%和4.8%(aRR=0.332,95%CI:0.153,0.721)。
  • 无论是否接种,<70岁成人PHN风险低于≥70岁者,女性风险与男性相似或更低。

关键数值与推荐

  • 疼痛采用Zoster Brief Pain Inventory(ZBPI)0-10分评估,切点为≥3、≥5、≥7。
  • PHN定义为90天时疼痛≥3分。

临床怎么用

  • 对≥60岁人群接种ZVL可减少带状疱疹相关疼痛及PHN负担。

局限性

  • 原文未报告观察性研究评估新重组带状疱疹疫苗长期效果及对PHN保护益处的具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pain following herpes zoster (HZ) can persist for months and negatively impact quality of life. To evaluate the effect of zoster vaccine live (ZVL) on progression of pain following HZ, we conducted a prospective cohort study of HZ cases at Kaiser Permanente Southern California. METHODS: ZVL vaccinated and unvaccinated members aged ≥60 years with laboratory-confirmed HZ from January 18, 2012 to February 26, 2015 were followed up within 5 days of HZ diagnosis, and at 30, 60, and 90 days after diagnosis. Pain was assessed with the Zoster Brief Pain Inventory (ZBPI) on a 0-10 scale, using cut-points of ≥3, ≥5, and ≥7, with postherpetic neuralgia (PHN) defined as pain ≥3 at 90 days. Log binomial regression was used to estimate adjusted risk ratios (aRRs) and 95% confidence intervals (CIs) associated with pain, comparing vaccinated versus unvaccinated HZ patients. RESULTS: We interviewed 509 vaccinated and 509 unvaccinated HZ patients. ZVL was associated with significantly lower risks of HZ-related pain at all time-points. The risk of PHN in vaccinated and unvaccinated patients, respectively, was 9.2% and 15.4% (aRR = 0.594, 95% CI: 0.413, 0.854); 2.0% and 4.8% of these patients reported pain ≥7 (aRR = 0.332, 95% CI: 0.153, 0.721). Irrespective of vaccination, the risk of PHN was lower in adults aged <70 years versus those ≥70 years and was similar or lower in females versus males. CONCLUSION: We used laboratory confirmation of HZ cases and patient survey to show that aside from preventing HZ, ZVL reduced HZ-related pain and prevented PHN among vaccine recipients who experienced HZ. Observational studies will be needed to evaluate long-term effectiveness of the new recombinant zoster vaccine and its benefits in protecting patients against PHN.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bruxvoort KJ, Liang AS, Harpaz R, et al. Patient report of herpes zoster pain: Incremental benefits of zoster vaccine live. Vaccine. 2019. PMID: 31088744. doi:10.1016/j.vaccine.2019.04.095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。